Hepatitis B
B-United
EU CT Nummer: 2024-514507-33-00
Recruitment closed
A Phase 2b, multi-centre, randomised, partially placebo controlled, observer-blind study to investigate the safety andefficacy of sequential therapy with Daplusiran/Tomligisiranfollowed by bepirovirsen in participants with chronic hepatitis B virus on background nucleos(t)ide analogue therapy (B-United)
Objective
Functional healing, weaning of NA-therapy (HBsAG loss)
We are looking for patients with:
- HepB with current NA-therapy
No HIV/ HCV/ HDV co-infections
HBsAG > 100 IU/mL
HBV DNA < 90 IU/mL
If you are interested in the study, please speak to your family doctor or infectiologist. You can also contact us directly by email or via the contact form for more information.
B-SURE
EU CT Nummer: 2023-506867-33
Only internal recruitment
A prospective, multi-centre study (B-Sure) to evaluate long-term durability of treatment response in chronic hepatitis B participants with and without nucleos(t)ide therapy who have participated in a previous bepirovirsen treatment study